# Synchron Continues US Human Trials of Endovascular Brain-Computer Interface

> news · REPORTED · 2025-07-01

Synchron, a key competitor to Neuralink, continued its human trials in the US during this period with its endovascular BCI that is inserted into the brain through a blood vessel rather than open-skull surgery, serving patients with severe paralysis. No new funding or regulatory announcement was identified within the strict 14-day window.

About Synchron: Synchron is a medical device company developing an endovascular brain-computer interface called the Stentrode, which is implanted into the brain through the jugular vein rather than open-skull surgery, enabling people with paralysis to control computers and digital devices using neural signals.

- Company: Synchron
- Sector: neurotech
- Primary source: https://www.technologyreview.com/2025/01/16/1110017/what-to-expect-from-neuralink-in-2025/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.